The partnership with Roche validates C4T's TORPEDO® platform and provides non-dilutive funding. Traders should monitor milestone achievements and potential stock movement on future announcements, especially as DACs represent a novel modality with high upside in oncology.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $2.83entry
- T+1 · 7mo ago −10.42%α −10.36% · $2.54
- T+5 · 7mo ago +2.47%α −0.71% · $2.90
- T+20 · 6mo ago +3.53%α −4.03% · $2.93
- T+60 · 4mo ago +46.29%α +35.51% · $4.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
C4 Therapeutics announced a collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology targets, with an option for a third. C4T receives a $20 million upfront payment and is eligible for over $1 billion in potential milestone payments and future royalties.
Key Financial Metrics
Key Facts
- C4 Therapeutics entered a collaboration with Roche to develop degrader-antibody conjugates (DACs) for oncology targets.
- C4T will receive $20 million upfront and is eligible for over $1 billion in discovery, development, and commercial milestone payments.
- Roche will handle conjugation, preclinical/clinical development, and commercialization; C4T will design degrader payloads using its TORPEDO® platform.
- The deal includes tiered royalties on future sales, subject to reductions under certain circumstances.
Financial Impact
$20 million upfront and over $1 billion in potential milestones
Risk Factors
- Milestones are contingent on successful development and regulatory progress, which are uncertain.
- Royalty terms may be reduced under certain circumstances as outlined in the agreement.
- Failure of DAC candidates in preclinical or clinical stages could negatively impact valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270765 |
Track record
19 reports on CCCC
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers